Abstract The Italian society of colo-rectal surgery (SICCR) is dedicated to improving the study, prevention and management of the diseases of the colon, rectum and anus. One of the aims of the society is to establish guidelines to the treatment of these diseases. These guidelines are based on the international literature and on the best available evidence. Clinical practice guidelines are one of the most important instruments to provide therapeutic decision-making support, based on the best scientific evidence available at the time. Guidelines are advisory and not prescriptive, susceptible to continual variations secondary to innovations and new scientific evidence. These guidelines are a guide for all colo-rectal surgeons and physicians who approach anal cancer.
Introduction
Clinical practice guidelines are one of the most important instruments for any scientific society to provide some therapeutic decision-making support, based on the best scientific evidence available at the time.
Guidelines are advisory and not prescriptive, susceptible to continual variations secondary to innovations and new scientific evidence.
Italian society of colo-rectal surgery (Società Italiana di Chirurgia Colorettale; SICCR) guidelines are intended for the use of all colo-rectal surgeons, health care professionals and patients who desire information.
Methodology
A MedLine search of English language references was performed by using the following keywords: anal cancer, anal squamous cell carcinoma, anal carcinoma, anal intraepithelial neoplasia, anal tumors, anal canal carcinoma and anal margin carcinoma.
The Cochrane library was also reviewed. The levels of scientific evidence were adapted from Cook et al. [1] .
Epidemiology
Carcinoma of the anus is a rare entity that the incidence of which has been rising over the last two decades, and which constitutes 3 % of all gastrointestinal tract tumors.
In Western Europe, the average annual incidence of anal carcinoma is 1-3 cases per 100,000 with a female prevalence (two to four times that of men [2] ) and a highest incidence during the sixth and seventh decades of life [3] .
The annual incidence can be up to 35 per 100,000 in men who practice anal-receptive sexual intercourse, and those who are human immunodeficiency virus (HIV) positive have twice the risk of those who are not [2] .
In particular, squamous cell carcinoma (the other names, epidermoid or spinocellular, are no longer used) is the most common histological type of anal carcinoma and constitutes up to 80 % of all malignant anal tumors [4] .
The clinical presentation is non-specific and may include anorectal bleeding, soiling and pruritus. Pain and the progressive growth of an anal mass are among the presenting symptoms in only 1 of 3 cases [5] .
The mass size at diagnosis is about 3-4 cm [6] .
Etiology
Chromosome 11 deletions (11q22) or the short arm of chromosome 3 (3p22), environmental factors such as cigarette smoking, sexual orientation and a high number of sexual partners, anoreceptive intercourse, male homosexuality, viral infections of the anogenital area (human papillomavirus (HPV) virus type 16 and 18) and immunodeficiency are all considered as causative factors of anal cancer [3, 6, 7] . The introduction of antiretroviral drugs has improved the life expectancy of HIV-positive patients. This has contributed to increasing the incidence of anal cancer in this population.
HPV infection (type 16 in about 87 % of cases [8] ) and anogenital warts are closely associated with anal cancer. Anal canal lesions are more often HPV positive than perianal lesions. Ninety-five percent of anal canal cancer in women and 83 % in men is HPV positive while cancer located at the anal margin are HPV positive in only 80 % of women and 28 % of men [8] . Because of this high association with anal cancer, HPV is considered to be the most important causative factor much like in cases of cervical cancer [9] [10] [11] [12] .
In particular, HPV is involved in the pathogenesis of anal intraepithelial neoplasia (AIN) which progresses from dysplasia to invasive cancer. HPV type 16 seems to be associated with a higher risk of malignant transformation [13] .
Other viral infections such as herpes simplex virus (HSV) have been studied but are considered to play only a marginal role in disease progression.
Anatomy and histological variants of malignant tumors
In the IUCC, American Joint Committee on Cancer (AJCC) and World Health Organization (WHO) staging systems, the anal canal is described as the last part of the gastrointestinal tract extending from the anal ring at the level of the puborectalis muscle (where the rectum enters the pelvic floor) to the anal margin that is the junction of the hair-bearing skin and the non-keratinizing squamous epithelium of the distal anal canal.
Tumors of the anal canal can present different histological features. These guidelines refer to squamous cell carcinoma (including the so-called cloacogenic variant) which constitutes 80 % of all lesions of this area and derives from transitional and squamous cell epithelium. In some pathology literature, squamous cell carcinoma of the anal canal is also described according to additional histopathologic feature such as keratinization, presence of mucin and abundance of basement membrane-like material.
Less common is adenocarcinoma and mucinous adenocarcinoma of the anal glands or of fistula tracts that must be distinguished from very low rectal cancers. Other uncommon neoplasms of the anal canal include small cell carcinoma, carcinoid and other neuroendocrine tumors, malignant melanoma, squamous cell papilloma, papillary hidradenoma, keratoacanthoma, mesenchymal and neurogenic tumors, lymphoma, leiomyosarcoma and secondary tumors.
Tumors originating from the anal margin should be staged as skin cancer: they can be squamous cell cancer, basal cell cancer, Bowen's or Paget's disease. This is an important distinction as skin cancers rarely involve lymph nodes or lead to distant metastases [14] [15] [16] .
Cancer of the anal canal

Diagnosis
Patients complain of anal bleeding, pain and sensation of a mass in about 80 % of cases.
A disease-specific history and physical examination are mandatory to evaluate predisposing factors, tumor extension and lymph node involvement.
Tissue biopsy is needed to establish the diagnosis. Anorectal cytology may only be used as a screening tool [17] .
About 20 % of patients present with synchronous nodal disease while distant metastases develop in 10-17 % [18] [19] [20] [21] . Lesions growing above the dentate line usually metastasize to mesorectal, pararectal and retroperitoneal (paravertebral) nodes while those originating below the dentate line metastasize to inguinal and femoral lymph nodes. HIV-positive patients commonly present with palpable enlarged nodes that are found to be histologically positive only in 50 % of cases.
Sentinel lymph node (SLN) biopsy of inguinal nodes has been proven to be a simple, safe and effective method for staging patients with anal cancer. Accurate detection of inguinal node metastases with this technique could obviate the need for prophylactic inguinal radiotherapy and eliminate related morbidity (e.g., inguinal fibrosis, external genitalia edema, lower limb lymphedema, osteonecrosis of femoral head, small bowel injury) which subsequently develops in 33 % of irradiated patients [22] .
(Level of Evidence: III; Grade of Recommendation: B). During the diagnostic work up, endoscopic and radiologic evaluation should be performed. Colonoscopy is indicated in patients at risk for large bowel cancer and in Paget's perianal disease.
Endoanal ultrasound is useful in assessing sphincter involvement, tumor extension and local lymph node metastases. Endoanal ultrasound tumor-node-metastasis (uTNM) staging system was introduced in 2002 [23] .
Nowadays, only a few studies with small numbers have evaluated the role of endoanal ultrasound in anal cancer staging. To date its main role is follow-up evaluation of patients treated with chemoradiotherapy (CRT) for squamous cell tumor of the anal canal [24] . EUS staging of anal canal cancer is reported in Table 1 .
Computed tomography (CT) scanning should be performed in the pretreatment evaluation of anal cancer to exclude metastatic disease. Positron emission tomography (PET) scanning as an adjunct to CT identifies sites of metastasis not observed on CT in 25 % of cases [25] . Almost 20 % of patients with inguinal nodes that are negative on both physical examination and CT scan are positive on PET [26] .
PET/CT proved useful in initial staging perirectal/pelvic or inguinal lymph nodes, causing a change in radiation fields in 16-35 % of patients [25] [26] [27] [28] [29] . However, upstaging related to lymph node metastases might have been overestimated, as up to 31 % of inguinal metastases identified by PET/CT are reportedly false positives [30] .
(Level of Evidence: IV; Grade of Recommendation: C). Currently, inguinal lymph nodes are better staged by sentinel node biopsy [30] .
As far as the role of virology in the diagnostic process is concerned, diagnosis of HIV and/or HPV infection do not imply a worse prognosis and therefore do not influence the treatment plan, at least for patients with a CD4 count[200. However, in HIV-positive patients anal cancer may be multifocal.
(Level of Evidence: IV; Grade of Recommendation: B).
Role of screening
High-risk groups such as homosexual men, individuals who practice anal intercourse, immunodepressed individuals and women affected by cervical intraepithelial neoplasia (CIN) III should be screened for anal cancer and AIN. Screening should be performed with anal cytology and high-resolution anoscopy. HPV infection should be considered in the evaluation of the progression of precancerous lesions such as AIN to anal cancer [13] . Due to the close relationship of cervical cancer with HPV infection, a gynecological exam should be performed with the aim of screening for synchronous cervical cancer.
Role of vaccines
Prophylactic vaccines against human papillomavirus have shown nearly 100 % efficacy against high-grade lesions of the cervix, vulva and vagina in uninfected women under 26 years of age. These results suggest vaccines will have a role in the prevention of anal intraepithelial neoplasia and squamous cell carcinoma of the anus in both sexes [31, 32] .
Staging
The most recent TNM staging version, published by the AJCC [33] is based on clinical and surgical-pathological assessment and more precisely reflects prognostic factors, specifically the size of the tumor and the regional lymphatic spread (Table 2 ).
Treatment
Management of anal cancer has changed during the last decades from a purely surgical approach, with a 5-year survival rate ranging from 30 to 80 %, to combined CRT with surgery indicated in case of residual or recurrent tumor [34] . However, no significant change in overall survival has been reported so far [17, 19, 20, 22] when this approach is compared with traditional surgery.
A local surgical approach may be appropriate only for selected small lesions and for carcinoma in situ [35] . Tumor radiation alone is at times adopted for small lesions up to T2 with the radiation dose of 40-50 Gy and can be curative in 70-80 % of cases [6, 36] .
With a radiation field extended not only to the tumor site but also to the pelvis and inguinal lymph nodes, a success rate of 60-80 % can be achieved [37, 38] . To follow are the recommendations for the treatment of the most common presentations of the disease. Any T any N: polychemotherapy ? radiotherapy Radiotherapy (RT) with concurrent chemotherapy is the current standard of care for patients with localized squamous cell cancer of the anal canal.
The majority of patients treated with CRT have excellent outcomes, with 5-year overall survival rates of approximately 75 % [15, 19] .
(Level of Evidence: I; Grade of Recommendation: A) Since its introduction by Nigro in 1979 [39, 40] (5-Fu, mitomycin and radiation), several studies have demonstrated the greater efficacy of the association of RT with chemotherapy with lower rates of local failure and recurrence and a smaller number of patients requiring a colostomy when compared with RT alone [35] .
(Level of Evidence: I; Grade of Recommendation: A). Pelvic RT can cause late toxicity, adversely impact bowel and sexual function and adversely affect quality of life (QoL). Younger patients reported worse QoL scores.
Modern techniques of RT, such as intensity-modulated radiation therapy (IMRT), could potentially reduce toxicity by reducing the radiation dose to the anorectal region and genitalia.
The association of multiple chemotherapeutic agents with RT results in a better synergistic effect [16, 22, 41] is currently recommended.
(Level of Evidence: I; Grade of Recommendation: A). RT is usually delivered at a total dose varying between 45 and 59 Gy. Higher doses without prolonged breaks in treatment have been shown to be more effective. The need for a diverting colostomy increases with the increase in the RT dose. The above RT dose should ideally be delivered during a period of 6 weeks [16, [42] [43] [44] [45] .
(Level of Evidence: III; Grade of Recommendation: B).
In HIV-positive patients, a good tolerance of CRT can be predicted if the CD4 count is above 200 [46] . Stage II: T2 or 3, N0, M0: The cancer is larger than 2 cm in size, but it has not spread to nearby organs or lymph nodes. It has not spread to distant sites Local failure occurs in up to 30 % of patients and is equally divided between persistent (if the neoplasms is found up to 3 months after the end of CRT), progressive (if the neoplasm grows in size during the CRT) and recurrent (if the neoplasms reappears 3 or more months after the end of CRT). The waiting time from the end of CRT to the final evaluation of the treatment is considered to be 8-10 weeks. The duration of the interval between CRT and final evaluation is still under debate with some authors suggesting a longer period of observation.
Persistent disease is re-evaluated at 4 weeks, then, the cases where a regression is noted are followed. Those without regression as those clearly progressing are best treated with an abdominoperineal resection (APR) which is an effective option for this indication with a 5-year survival rate of 24-58 % [47] .
(Level of Evidence III; Grade of Recommendation: B). Survival after APR resection is longer for patients with persistent disease compared with patients with recurrent disease [7, 22, [47] [48] [49] [50] [51] . APR may also be beneficial in the treatment of local RT-induced complications such as stenosis, ulceration or incontinence. An additional boost of CRT has been suggested in a small number of reports but its efficacy is debated [17] .
In case of progressive disease, no response to CRT, extrapelvic recurrence or local recurrence after APR, treatment with multiple chemotherapeutic agents is indicated [52, 53] .
(Level of Evidence III; Grade of Recommendation: B). Synchronous inguinal lymph node involvement completely regresses after CRT in 90 % of cases [15] .
Metachronous lymph node involvement, seen in 10-20 % of patients, usually within 6 months from the end of treatment, may also respond to CRT [41] .
In case of persistent lymph node disease, surgical removal is indicated.
Follow-up
A clinical evaluation with digital rectal examination, proctoscopy and abdominal-inguinal palpation is recommended.
Follow-up with serial endoanal ultrasound has recently gained popularity but the results are still preliminary [23, 24] .
(Level of Evidence: IV; Grade of Recommendation: B). Follow-up begins at 6-12 weeks after the end of CRT and needs to be repeated every 3-6 months. Endorectal ultrasound (ERUS) and CT scan indicated in case recurrence are suspected [7, [54] [55] [56] .
The proposed flow chart showing the diagnostic and therapeutic algorithm for anal canal cancer is reported in Table 3 .
Anal margin
Diagnosis
It may be difficult to differentiate between anal margin and anal canal in the case of large tumors.
The differential diagnosis between anal canal and anal margin tumors is useful because of the difference in treatment and prognosis (generally better for anal margin lesions) between the two [6] .
Bowen's and Paget's diseases of the anal margin can be associated with other malignancies (5 % for Bowen up to 50 % for Paget) [6] .
This extramammary form of Paget's represents less than 1 % of anal disease and 6.5 % of all cases of Paget's disease [6] .
This tumor can recur after radical surgery and has a capacity of metastatic spread: its aggressive behavior imposes a long-term follow-up with frequent clinical, radiological and endoscopic controls.
The diagnostic work up for anal margin tumors is that the same as the one highlighted for anal canal tumors.
Clinical staging
Anal margin squamous cell carcinomas are staged like skin cancer, according to the AJCC [33] .
Treatment
A local excision (1 cm margin) is indicated in early squamous lesions such as T1, N0,\2 cm, microinvasive or carcinoma in situ, and well-differentiated tumors, similarly to skin lesions, with a 80 % 5-year survival rate [57] .
In case of more extended lesions or doubtful inguinal or regional lymph nodes, adjuvant radiation therapy is suggested.
More locally advanced lesions such as T3 or T4 need to be treated with radiation of either inguinal regions or pelvis associated with chemotherapy as previously described for anal canal lesions.
A more extended surgical approach such as APR is indicated in case of CRT failure and in case of incontinent patients with large, bulky cancers infiltrating the sphincter and pelvic muscles.
The proposed flow chart showing the diagnostic and therapeutic algorithm for cancer of anal margin is reported in Table 4 .
Anal intraepithelial neoplasia AIN has been called, among other things, dysplasia, carcinoma in situ, anal squamous intraepithelial lesion, Bowen's
disease. It has some characteristics in common with CIN and in fact is classified according to cervical cytology. High-grade anal intraepithelial neoplasia, also referred to as anal squamous carcinoma in situ, or Bowen's disease of the anus, make up less than 1 % of all digestive system cancers.
They can be accidentally found in the anal transitional area as in the anal margin area.
AIN is considered as a precursor to anal squamous cell carcinoma: AIN Grade 1 correspond to low-grade squamous intraepithelial lesion (LSIL), AIN II-III stands for high-grade squamous intraepithelial lesion (HSIL) that is sometimes referred to as anal carcinoma in situ and Bowen's disease.
Up to 80 % of AIN are believed to develop from HPV 16 and 18 infections.
Diagnosis
Incidentally diagnosed, they can present as an eczematoid area with papules, often white, irregular and fissured.
A high-level suspicious history should be taken, with particular attention to signs, symptoms and predisposing factors.
Basic diagnostic work up includes clinical inspection of the perianal area, digital rectal examination, and anal cytology.
These lesions are more common in HIV patients, especially in HIV-positive men having sex with men (MSM).
A compromised immune system, both in male and in female is an important risk factor. HIV seropositivity, like immunosuppression for organ transplantation or for specific diseases, is associated with AIN and its progression to high-grade squamous intraepithelial lesions. This progression has been observed to occur in about 10-50 % of HIV-positive patients within 2 years [58, 59] .
HPV infection associated with AIN is well demonstrated. Despite the limited data available about the pathophysiologic effects of HPV (subtypes 16 and 18), a loss of tumor suppressor protein p53 has been described as well as some gene aberrations and alterations [58] .
These associations can be simply superimposed with cervical cancer natural history [60] [61] [62] .
As reported for CIN, Papanicolaou smear cytological examination can be used for screening and follow-up of AIN.
(Level of Evidence III; Grade of Recommendation: C). Nevertheless, high-resolution anoscopy-directed biopsy is still considered as the gold standard for AIN diagnosis.
Treatment
The treatment of choice is surgical resection with anal mapping.
Although the main treatment modality for treating persistent/recurrent AIN is surgery, an alternative approach using external beam radiation has been proposed.
As a well-established precursor of squamous cell carcinoma, AIN observation is not considered an appropriate strategy [63] .
(Level of Evidence: IV; Grade of Recommendation: C). New drugs with an immunomodulatory effect, such as 5 % imiquimod cream (response rate more than 50 %) [64] or chemotherapeutics such as 5 % 5-fluorouracil cream (initial response rate of 90 %) are indicated for AIN [65] .
(Level of Evidence: IV; Grade of Recommendation: C). Photodynamic therapy has been suggested in some cases, but its effectiveness has been shown only in case reports [66] .
(Level of Evidence: V; Grade of Recommendation: D). Surgical excision (wide local excision, targeted destruction, infrared coagulation) and careful clinical follow-up similar to what is indicated for CIN have been adopted to treat AIN and to prevent its progression [67] [68] [69] [70] .
(Level of Evidence: III; Grade of Recommendation: C).
Follow-up
Considering the risk of progression to squamous cell carcinoma, surveillance is mandatory. This can be performed at 6-month follow-up unless dysplasia is still present. High-resolution anoscopy with magnification and/or the application of Lugol's solution can be performed especially in those patients with risk factors [70] . Table 5 .
Verrucous carcinoma
This tumor, also called giant condyloma (BuschkeLowenstein tumor), appears as a cauliflower-like lesion that can involve the anogenital area.
Some of these lesions are HPV positive (subtypes 6 and 11).
Intermediate between classical condyloma and squamous cell cancer, it is characterized by a local invasive behavior with a combination of exophytic and endophytic growth with very rare metastasis and a variable risk of showing malignant transformation (around 42 %) [71] .
Diagnosis
It presents like an exophytic tumor of the genital or perianal area, with ulceration and sometimes fistulae and sinuses. It is more commonly seen in men than in women (2-3 vs. 1) and immunocompromised patients.
The histological appearance of this cancer is similar to that of condyloma acuminata, but with a tendency to compress and displace deeper tissues, without basement membrane disruption.
Physical examination and a dedicated diagnostic work up (the same as the one highlighted for anal canal and margin tumors) are useful to choose the right treatment regimen.
Treatment
A wide local excision is indicated to avoid malignant transformation, and because of the high number of recurrences.
Other treatment modalities such as chemotherapy or imiquimod may be attempted to avoid mutilating surgical interventions [72] .
Follow-up
An established and rigorous follow-up is necessary because of frequent recurrences and possible malignant transformation.
Conclusions
Cancer of the anal canal is still a challenge. Despite the efficacy showed by the introduction of RT into the treatment plan, a lot of work needs to be done to better define this disease.
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